Cardiol Therapeutics  logo
CRDLCardiol Therapeutics
Trade CRDL now
Cardiol Therapeutics  primary media

About Cardiol Therapeutics

Cardiol Therapeutics (TSX:CRDL), (NASDAQ:CRDL) is a biotechnology company focused on researching and developing innovative cannabidiol (CBD) treatments for heart diseases and other medical conditions. With a commitment to scientific excellence, Cardiol's projects include the development of anti-inflammatory therapies aimed at reducing the risk of cardiovascular diseases and improving patient outcomes. The company's objectives center around leveraging their proprietary technologies and pharmaceutical expertise to lead the way in developing safer, more effective CBD-based medicines. Cardiol Therapeutics Class A is also traded on the Nasdaq under the ticker code (NASDAQ:CRDL), enabling a broader international investment base to support its mission in transforming cardiovascular treatment landscapes.

What is CRDL known for?

Snapshot

Public US
Ownership
2017
Year founded
26
Employees
Oakville, Canada
Head office
1 of 6
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Oakville, CA

Products and/or services of Cardiol Therapeutics

  • Development of CardiolRx, a pharmaceutically produced cannabidiol formulation for treating heart failure and inflammatory heart disease.
  • Clinical trials for anti-fibrotic and anti-inflammatory therapies targeting cardiovascular diseases.
  • Research on small molecules for treating fibrotic diseases, including myocarditis and heart failure.
  • Collaboration on the formulation and clinical development of new drug candidates designed to protect heart tissue after acute events.
  • Partnerships for advancing the development of diagnostic and therapeutic technologies in cardiovascular medicine.
  • Outreach and education initiatives aimed at increasing awareness of heart diseases and the potential benefits of cannabidiol-based treatments.

Cardiol Therapeutics executive team

  • Mr. David G. Elsley MBAPresident, CEO & Director
  • Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBACFO, Corporate Secretary & Director
  • Mr. Bernard Lim B.Sc.Chief Operating Officer
  • Dr. Andrew Warwick Hamer M.D.Chief Medical Officer and Head of Research & Development
  • Trevor BurnsInvestor Relations
  • Mr. John A. Geddes BSCPT, MBAVice President of Corporate Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.